Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

ed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live call.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional Phase 3 trials planned to begin this year in both Alzheimer's disease and Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the timing of: initiation of clinical studies, filing of an NDA for Dimebon, seeking approval to commence a Phase 3 trial of MDV3100, the presentation of data with respect to Dimebon and MDV3100 and the receipt of milestone payments as well as the extent of future expected financial results, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of his
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Warren, NJ (PRWEB) May 22, 2015 ... a new white paper that explores the potential of ... industries. The white paper was developed to help life ... they can leverage data to gain critical business insights. ... generated large amounts of data driven by patient profiling, ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... sciences company that develops and commercializes proprietary technologies and ... and operational results for the second fiscal quarter ended ... the Company continued to advance business with our existing ... Morris , President and CEO of SQI. "The delivery ...
(Date:5/21/2015)... 2015 Specialty Pharmacy Times has ... admitted to BPA Worldwide as a business publication ... audience data for Specialty Pharmacy Times based on ... becoming a member of BPA Worldwide, Specialty Pharmacy ... clients with the most reliable, unequaled data,” said ...
(Date:5/21/2015)... YORK , May 21, 2015  Prima Biomed ... company that is striving to become a leader in ... cancer, recently announced that the final CVac data from ... shown a clear trend for a clinically meaningful improvement ... in second remission patients. In the group ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2
... NEW YORK, Nov. 16, 2011 Oligomerix, Inc. ... in Washington D.C. which demonstrated that tau protein ... function. This proteolytic function results in tau,s self-fragmentation ... a mechanism for its neurotoxic mode-of-action. Furthermore, certain ...
... Kan., Nov. 16, 2011 The Kansas Bioscience Authority ... ended June 30, and cumulative outcomes since the KBA,s ... investments, are reported annually based on information provided by ... full-time jobs created by bioscience companies in Kansas; ...
... DIEGO, Nov. 16, 2011 ... United States Patent and Trademark Office has granted a ... as Thiazovivin.  U.S. Patent No. 8,044,201 entitled "Stem Cell ... inhibitor, as well as compositions and cell culture media ...
Cached Biology Technology:A New Mechanism for Tau Protein Pathology in Alzheimer's Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting 2Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 2Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 3Fate Therapeutics Strengthens Its iPSC Platform 2Fate Therapeutics Strengthens Its iPSC Platform 3
(Date:5/19/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... to treat heroin addicts for nearly 50 years. Yet ... from prolonged use. New research from the Norwegian Institute ... and impairs the attention of experimental animals. ... known to weaken intellectual functions such as learning, memory ...
... team has discovered that insects that bore into trees as long ... a calling card that,s rich with information. The information is ... Resin is produced in large quantities by a tree when it,s ... is under an attack from boring insects researchers have sometimes had ...
... early in pregnancy may have a profound and long-lasting effect ... lack of iron is not enough to cause severe anemia, ... in the scientific journal PLoS One . The ... mild or moderate iron deficiency, and therefore the study authors ...
Cached Biology News:Long-term methadone treatment can affect the brain 2Tree resin the key evidence of current and historic insect invasions 2Pre-conception and early pregnancy iron deficiency harms brain 2Pre-conception and early pregnancy iron deficiency harms brain 3
... to BRF2 Immunogen Synthetic peptide: QAARQAATSVPNPP, ... Human BRF2. Reactivity / Specificity Cross-reacts ... Background Information BRF2 is one of ... transcription factor complex required for transcription of genes ...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Goat polyclonal to Als2 ( Abpromise for all tested applications). entrezGeneID: 57679 SwissProtID: Q96Q42...
Biology Products: